ReviewWorld journal of gastroenterology2016
Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer.
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients.Scientific reports · 2018Trial
- An integrative mutational and network analysis of pancreatic cancer reveals key genes, and signalling pathways.Functional & integrative genomics · 2026Article
- 4D-printed microdevices for spatiotemporal detection of ctDNA and miRNA in pancreatic cancer: an in-depth review.Medical oncology (Northwood, London, England) · 2025Review
- Bridging the gap: The role of technological advances in shaping gastrointestinal oncological outcomes.World journal of gastrointestinal oncology · 2025Article
- Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection.Frontiers in oncology · 2023Article
- The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy.Cancers · 2022Review
- Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma.Frontiers in oncology · 2022Article
- Liquid Biopsy, ctDNA Diagnosis through NGS.Life (Basel, Switzerland) · 2021Review
- The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives.Signal transduction and targeted therapy · 2021Review
- Molecular profiling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2021Review
- Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Cultures.Cancers · 2020Article
- Article
- Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis.PloS one · 2020Article
- Review
- Next-generation sequencing and its clinical application.Cancer biology & medicine · 2019Article
- The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer.Canadian journal of gastroenterology & hepatology · 2018Review
- Clinical utility of circulating cell-free Epstein-Barr virus DNA in patients with gastric cancer.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most pancreatic cancer patients present with advanced metastatic disease, resulting in extremely poor 5-year survival, mainly because of the lack of a reliable modality for early detection and limited therapeutic options for advanced disease. Therefore, there is a need for minimally-invasive diagnostic tools for detecting pancreatic cancer at an early stage, when curative surgery and also novel therapeutic approaches including precision medicine may be feasible. The "liquid biopsy" addresses these unmet clinical needs based on the concept that simple peripheral blood sampling and detection of circulating tumor DNA (ctDNA) could provide diagnostic information. In this review, we provide an overview of the current status of blood-based tests for diagnosis of pancreatic cancer and the potential utility of ctDNA for precision medicine. We also discuss challenges that remain to be addressed in developing practical ctDNA-based liquid biopsy approaches for early diagnosis of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.